Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer.

Garcia-Recio, Susana; Fuster, Gemma; Fernandez-Nogueira, Patricia; Pastor-Arroyo, Eva M; Park, So Yeon; Mayordomo, Cristina; Ametller, Elisabet; Mancino, Mario; Gonzalez-Farre, Xavier; Russnes, Hege G; Engel, Pablo; Costamagna, Domiziana; Fernandez, Pedro L; Gascón, Pedro; Almendro, Vanessa

Garcia-Recio, Susana; Fuster, Gemma; Fernandez-Nogueira, Patricia; Pastor-Arroyo, Eva M; Park, So Yeon; Mayordomo, Cristina; Ametller, Elisabet; Mancino, Mario; Gonzalez-Farre, Xavier; Russnes, Hege G; Engel, Pablo; Costamagna, Domiziana; Fernandez, Pedro L; Gascón, Pedro; Almendro, Vanessa.

Affiliation

Garcia-Recio S; Authors' Affiliations: Department of Medical Oncology and Pathology, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Department of Medicine, University of Barcelona; Department of Cell Biology, Immunology, and Neurosciences, Medical School, University of Barcelona, Barcelona, Spain; Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea; Department of Genetics, Oslo University Hospital Radiumh

Cancer Res ; 73(21): 6424-34, 2013 Nov 01.

Article de En | MEDLINE | ID: mdl-24030979

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du sein / Substance P / Régulation de l'expression des gènes tumoraux / Récepteur ErbB-2 / Résistance aux médicaments antinéoplasiques / Communication autocrine Type d'étude: Prognostic_studies Limites: Female / Humans Langue: En Journal: Cancer Res Année: 2013 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google